Efficacy and safety of co-administered cagrilintide and semaglutide (CagriSema) 1.0 mg/1.0 mg s.c. once weekly versus tirzepatide 5 mg s.c. once weekly in participants with type 2 diabetes inadequately controlled on metformin, SGLT2 inhibitor or both
RecruitingCTIS2023-509600-15-00
Novo Nordisk A/SType 2 Diabetes
Start: 2024-10-18Target: 410Updated: 2025-11-10